以“数据+AI”赋能创新药商业化落地 镁信健康发布多元支付智策平台

Core Insights - The Chinese innovative pharmaceutical industry is transitioning from a single payment system to a multi-payment mechanism, which is essential for unlocking the potential of commercial insurance markets [3] Group 1: Industry Development - The innovative drug industry in China has experienced rapid growth, with annual R&D investment continuously increasing and several original new drugs successfully entering international markets [1] - The traditional commercialization strategy relying solely on medical insurance as a payment source is no longer suitable, necessitating a shift towards a multi-payment strategy [2] Group 2: New Payment Mechanism - The launch of the AI + data intelligent central platform mind42.ai by Meixin Health aims to provide intelligent decision support for pharmaceutical companies in a multi-payment environment, facilitating the optimal commercialization of innovative drugs [1][2] - The platform integrates various data sources, including insurance claims, drug information, prescription data, and macroeconomic data, to create a comprehensive data system for precise decision-making [2] Group 3: Collaboration and Future Outlook - Meixin Health has partnered with major pharmaceutical companies such as AstraZeneca, Bristol-Myers Squibb, Pfizer China, Roche, and Zai Lab to enhance the commercialization process of innovative drugs [3] - The company believes that the multi-payment era for innovative drugs has arrived and aims to empower the commercialization process, facilitating a positive cycle from investment to R&D to returns [3]